Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review

被引：6

作者：

Peyrade, Frederic ^{[1
]}

Triby, Caroline ^{[1
]}

Slama, Bohane ^{[2
]}

Fontana, Xavier ^{[1
]}

Gressin, Remy ^{[3
]}

Broglia, Jean-Marc ^{[2
]}

Lepeu, Gerard ^{[2
]}

Carrier, Patricia ^{[1
]}

Peyrottes, Isabelle ^{[1
]}

Darcourt, Jacques ^{[1
]}

Bondiau, Pierre-Yves ^{[1
]}

Thyss, Antoine ^{[1
]}

机构：

[1] Ctr Antoine Lacassagne, F-06054 Nice, France

[2] Ctr Hosp Avignon, Avignon, France

[3] CHU Grenoble, F-38043 Grenoble, France

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 09期

关键词：

follicular lymphoma; ibritumomab tiuxetan; autologous bone marrow transplantation;

D O I：

10.1080/10428190802273278

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multicenter, retrospective study of standard-dose RIT in eight heavily pre-treated patients with CD20-positive follicular lymphoma who had relapsed after previous autologous bone marrow transplantation (ABMT). Patients underwent nine courses of (90)Y-ibritumomab tiuxetan (0.3 or 0.4 mCi/kg body weight). Responses included five CR, two PR, one SD and one PD. Median DFS was 12 months with median follow-up of 17 months and 1-year OS was 83% (7/8 patients). Grade 4 thrombocytopenia occurred in 7/9 treatments, with no episodes of bleeding, and only two patients received a platelet transfusion. One patient, who had 20% bone marrow involvement at the time of relapse diagnosis, presented with Grade 4 thrombocytopenia and Grade 4 neutropenia and died of septic shock 6 months after RIT. One other case of Grade 4 neutropenia, without a serious infectious syndrome, was observed. Standard-dose RIT seems feasible and potentially effective after ABMT in correctly selected patients with follicular lymphoma.

引用

页码：1762 / 1768

页数：7

共 26 条

[1] High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol [J].

Brice, P ;

Simon, D ;

Bouabdallah, R ;

Bélanger, C ;

Haïoun, C ;

Thieblemont, C ;

Tilly, H ;

Harousseau, JL ;

Doyen, C ;

Martin, C ;

Brousse, N ;

Solal-Céligny, P .

ANNALS OF ONCOLOGY, 2000, 11 (12) :1585-1590

[2] Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission [J].

Brown, Jennifer R. ;

Feng, Yang ;

Gribben, John G. ;

Neuberg, Donna ;

Fisher, David C. ;

Mauch, Peter ;

Nadler, Lee M. ;

Freedman, Arnold S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (09) :1057-1065

[3] Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma [J].

Buchegger, F. ;

Antonescu, C. ;

Delaloye, A. Bischof ;

Helg, C. ;

Kovacsovics, T. ;

Kosinski, M. ;

Mach, J-P ;

Ketterer, N. .

BRITISH JOURNAL OF CANCER, 2006, 94 (12) :1770-1776

[4] High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience [J].

Cao, TM ;

Horning, SF ;

Negrin, RS ;

Hu, WW ;

Johnston, LF ;

Taylor, TL ;

Shizuru, JA ;

Hoppe, RT ;

Brown, BW ;

Blume, KG ;

Stockerl-Goldstein, K .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (05) :294-301

[5] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[6] Treatment-related Myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy [J].

Czuczman, Myron S. ;

Emmanouilides, Christos ;

Darif, Mohamed ;

Witzig, Thomas E. ;

Gordon, Leo I. ;

Revell, Stephen ;

Vo, Katie ;

Molina, Arturo .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4285-4292

[7] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma [J].

Davies, AJ ;

Rohatiner, AZS ;

Howell, S ;

Britton, KE ;

Owens, SE ;

Micallef, IN ;

Deakin, DP ;

Carrington, BM ;

Lawrance, JA ;

Vinnicombe, S ;

Mather, SJ ;

Clayton, J ;

Foley, R ;

Jan, H ;

Kroll, S ;

Harris, M ;

Amess, J ;

Norton, AJ ;

Lister, TA ;

Radford, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1469-1479

[8] High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS [J].

Deconinck, E ;

Foussard, C ;

Milpied, N ;

Bertrand, P ;

Michenet, P ;

Cornillet-LeFebvre, P ;

Escoffre-Barbe, M ;

Maisonneuve, H ;

Delwail, V ;

Gressin, R ;

Legouffe, E ;

Vilque, JP ;

Desablens, B ;

Jaubert, J ;

Ramee, JF ;

Jenabian, A ;

Thyss, A ;

Le Pourhiet-Le Mevel, A ;

Travade, P ;

Delepine, R ;

Colombat, P .

BLOOD, 2005, 105 (10) :3817-3823

[9] Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas [J].

Fisher, RI ;

Kaminski, MS ;

Wahl, RL ;

Knox, SJ ;

Zelenetz, AD ;

Vose, JM ;

Leonard, JP ;

Kroll, S ;

Goldsmith, SJ ;

Coleman, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7565-7573

[10] High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission [J].

Freedman, AS ;

Gribben, JG ;

Neuberg, D ;

Mauch, P ;

Soiffer, RJ ;

Anderson, KC ;

Pandite, L ;

Robertson, MJ ;

Kroon, M ;

Ritz, J ;

Nadler, LM .

BLOOD, 1996, 88 (07) :2780-2786

← 1 2 3 →